Trials / Not Yet Recruiting
Not Yet RecruitingNCT05087784
AlloLife - Life After Transplantation
AlloLife - Life After Allogeneic Hematopoietic Stem Cell Transplantation
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 192 (estimated)
- Sponsor
- University Hospital, Essen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Survivors of allo HCT can experience long-term survival, which is however limited by a number of late effects. These will be addressed in AlloLife to improve quality of life (QoL) and survival.
Detailed description
The complex intervention in AlloLife will consist of a set of technically-supported tools that will enable active care management through the patient and treating physician to improve QoL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps | Patient-centered, technology-supported integrated survivorship- and care management |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2025-12-01
- Completion
- 2026-06-01
- First posted
- 2021-10-21
- Last updated
- 2021-11-16
Source: ClinicalTrials.gov record NCT05087784. Inclusion in this directory is not an endorsement.